Are Doctors Prescribing More Due to Pharma Influence?

Two lab researchers reviewing documents behind frosted glass

Yet again, a study finds that doctors who are paid or given gifts by pharma companies are more likely to prescribe more drugs from those companies. Of course they do. Why would they not? Doctors are influenced by money, and this is where the concept of Pharma Influence comes into play. So what? Doctors could be prescribing drugs that aren’t as good for patients. But aren’t we missing a bigger question here? Are doctors prescribing worse drugs? Or are they prescribing drugs that are equally as good but just different?

What I think is missing from these discussions is this. If a doctor is paid by a pharma company, they are more likely to prescribe more of those drugs. Yes, there is a correlation. But is that a bad thing?

Could the drug that doctor is now prescribing be more costly to the patient or the health system but yield the same results as a competing product? These are questions that need to be answered. We can’t simply say that because a doctor was paid by a pharma company and prescribed more of their drug, something went wrong.

Are There More Bad Drugs Being Prescribed Because Of Pharma Payments?

Understanding pharma influence on prescribing habits is crucial to evaluating the healthcare system.

We have an abundance of drugs on the market today. Many compete against each other within their class of drugs. Some drugs can have minimal differences that may or may not impact a patient. There are some classes of drugs that are more competitive than others. Such as statins, proton pump inhibitors, antidepressants, and a few classes of blood pressure drugs.

If a doctor is paid by a company and starts prescribing more of its drug. But that drug may have minimal or no difference in outcome from another drug that competes with it. What have we learned from that research?

Maybe we’ve learned that marketing works.

Not that the patient is being harmed. Now, if that drug is more expensive and yields the same result as a competing generic, we may want to consider that. Patients would be paying more for the same results. Which is never good. But that doesn’t mean the patient is getting worse results because a doctor was paid by that company.

Some drugs may be prescribed because a doctor was paid by that company. Others may not. But just because a doctor is paid by a pharma company and they start prescribing more of those drugs. It doesn’t mean the patient is getting a worse drug.

We Need to Know What Types of Drugs Doctors Paid by Pharma Prescribe.

Let’s say we have 2 doctors. Both were paid by pharma companies. Doctor A now prescribes more of their brand-name acid reflux drug that costs more than a generic. Meanwhile, Doctor B starts prescribing more of their drug, which provides better results for a specific patient population. This study could include both doctors and find that they prescribe more of that company’s drug. But what does that really mean?

We need to know whether that drug provides any benefit to the patient over what is currently available. Is it a first-in-kind drug? Does it have any significant benefit over competitors? Is it a drug that many competitors are on the market for? Ask these questions to determine whether pharma payments are affecting doctors’ prescribing habits.

What We Know From The New Cochrane Study.

On October 9th 2026, a new Cochrane review was released. It reviewed 93 studies, 62 of which focused on gifts and payments. They found that gifts and payments were associated with more prescribing and inappropriate prescribing. 39 studies included around 3.8 million doctors and examined how many drugs they prescribed. And 10 studies looked at around 2.9 million doctors and inappropriate prescribing.

We need to take this seriously.

But we don’t know which drugs they are or what that means for our patients. Are doctors prescribing worse drugs that cost more? Or are we just seeing more drugs being prescribed from pharma companies that pay doctors?

Screenshot

Pharma Has An Abundance Of Drugs On The Market Today.

Pharma sells many drugs that have minimal or no benefit to patients over other drugs on the market. Some are better than others. Some may provide no benefit at all. We need to understand that some of these drugs may only have small benefits that can go unnoticed. Which leads me to my next point.

Marketing.

If a drug offers no significant benefit over competitors, you can bet pharma will spend money to get it in front of doctors. Whether that be giving them money or meals doesn’t matter. It’s about getting your drug in front of them and having them think your drug is the best choice for their patient. We need to dig deeper into these studies and see which drugs doctors who receive payments from pharma are prescribing more often.

Are these doctors prescribing drugs that have no benefit over other drugs on the market? If so we need to look at why. If not, then maybe we are overreacting to these findings.

I Don’t think we need to worry about doctors prescribing more drugs from pharma companies that pay them.

What I think we need to worry about is doctors that are paid by pharma companies and start to prescribe drugs that have no benefit to patients. Or may even have negative outcomes. That is when we should be concerned. But just because a doctor was paid by a pharma company and they started prescribing more of their drugs doesn’t mean the patient is being harmed.

There is a fine line between what is considered okay and what isn’t. Doctors who are paid by pharma companies to speak at conferences or write papers should not be frowned upon. As long as they are disclosing that information to their patients. But if a doctor receives payments from a pharma company and starts prescribing more of its drugs, even when it doesn’t benefit patients, then we have a problem.

References:

Cochrane Review on Pharma Company Marketing and Doctors Prescribing Habits. Published October 2026. Studies reviewed up to January 2025.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply